Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis

Overview

Journal J Clin Rheumatol Musculoskelet Med

Date 2013 Apr 30

PMID 23626904

Authors

Edward A Pankey

Matthew Epps

Bobby D Nossaman

Albert L Hyman

Philip J Kadowitz

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease with limited therapeutic options. Moreover, when PAH occurs in patients diagnosed with systemic sclerosis, worse outcomes are observed. The purpose of this review is to discuss the etiologies of PAH found in the systemic sclerosis patient, limitations of current medical therapies, and, finally, potential therapies for patients with this combination.

References

Johnson S, Mehta S, Granton J . Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006; 28(5):999-1004. DOI: 10.1183/09031936.06.00015206. View

Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52(12):3792-800. DOI: 10.1002/art.21433. View

Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L . RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009; 179(12):1151-8. DOI: 10.1164/rccm.200805-691OC. View

Tyndall A, Gratwohl A . The use of high dose immunoablative therapy with hematopoietic stem cell support therapy in the treatment of severe autoimmune diseases. Int J Hematol. 2002; 76 Suppl 1:218-22. DOI: 10.1007/BF03165249. View

Abraham D, Vancheeswaran R, Dashwood M, Rajkumar V, Pantelides P, Xu S . Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997; 151(3):831-41. PMC: 1857854. View

Rabinovitch M . Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2008; 118(7):2372-9. PMC: 2439479. DOI: 10.1172/JCI33452. View

Sztrymf B, Yaici A, Girerd B, Humbert M . Genes and pulmonary arterial hypertension. Respiration. 2007; 74(2):123-32. DOI: 10.1159/000098818. View

Condliffe R, Kiely D, Peacock A, Corris P, Gibbs J, Vrapi F . Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2008; 179(2):151-7. DOI: 10.1164/rccm.200806-953OC. View

Fonseca C, Renzoni E, Sestini P, Pantelidis P, Lagan A, Bunn C . Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 2006; 54(9):3034-42. DOI: 10.1002/art.22036. View

10.

Le Pavec J, Humbert M, Mouthon L, Hassoun P . Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 181(12):1285-93. PMC: 2894407. DOI: 10.1164/rccm.200909-1331PP. View

11.

Steen V, Medsger Jr T . Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003; 48(2):516-22. DOI: 10.1002/art.10775. View

12.

Sabnani I, Zucker M, Rosenstein E, Baran D, Arroyo L, Tsang P . A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2008; 48(1):49-52. DOI: 10.1093/rheumatology/ken369. View

13.

Kawut S, Horn E, Berekashvili K, Lederer D, Widlitz A, Rosenzweig E . Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006; 19(5):370-4. DOI: 10.1016/j.pupt.2006.01.001. View

14.

Varga J . Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum. 2002; 46(7):1703-13. DOI: 10.1002/art.10413. View

15.

Austin E, Loyd J, Phillips 3rd J . Genetics of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009; 30(4):386-98. PMC: 3737593. DOI: 10.1055/s-0029-1233308. View

16.

Fox D, Khattar R . Pulmonary arterial hypertension: classification, diagnosis and contemporary management. Postgrad Med J. 2006; 82(973):717-22. PMC: 2660498. DOI: 10.1136/pgmj.2006.044941. View

17.

Machado R, James V, Southwood M, Harrison R, Atkinson C, Stewart S . Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation. 2005; 111(5):607-13. DOI: 10.1161/01.CIR.0000154543.07679.08. View

18.

Patterson K, Weissmann A, Ahmadi T, Farber H . Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006; 145(2):152-3. DOI: 10.7326/0003-4819-145-2-200607180-00020. View

19.

Badesch D, McGoon M, Barst R, Tapson V, Rubin L, Wigley F . Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009; 36(10):2244-9. DOI: 10.3899/jrheum.081277. View

20.

Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M . Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem. 2009; 4(5):853-65. DOI: 10.1002/cmdc.200900014. View